Inclusion Criteria:

- Signed informed consent prior to participation in the study.

- Male or female participants aged 18 years and older on the day of signing informed
consent

- Primary ITP diagnosed within 3 months before initiating first-line ITP therapy
(corticosteroids, IVIG)

- Platelet count below 30 G/L before starting any first-line ITP therapy
(corticosteroids, IVIG)

- Response (platelet count >=50 G/L) to corticosteroids (+/- IVIG) at any time prior to
randomization. Note: Platelet count measured within 7 days of platelet transfusion
will not be considered as response.

Key Exclusion Criteria:

- Evans syndrome or any other cytopenia

- Current life-threatening bleeding

- Previous ITP treatment, including splenectomy, except for corticosteroids and/or IVIG
initiated as first-line therapy for up to 28 days before randomization and rescue
corticosteroids and/or IVIG given prior to confirmed diagnosis of primary ITP .

- Prior use of B-cell depleting therapy (e.g., rituximab).

- Absolute neutrophil count below 1.0 G/L at randomization

- Participants with concurrent coagulation disorders and/or receiving anti-platelet or
anticoagulant medication with an exemption of low dose of acetylsalicylic acid

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 10/18/23. Questions regarding updates should be directed to the study team contact.